biotech startups, VC @ TVC @ 1bio | #FirstGen 🇺🇲 & 👨‍🎓 | MS/MBA @Wharton @Tufts | Boston/SF/Philly/NY/ - opinions my own & subject to change

Joined December 2015
Chris Ghadban retweeted
With @WSJ and @georgia_wells we are now sharing a bit more about our work at @redqueenbio : using AI and a lot of hard wet lab work to create medicines that let us prepare for both natural and synthetic viruses in advance.
9
42
7
290
103,139
Chris Ghadban retweeted
1/4 Research log 1: 190 million people live with endometriosis, and I'm an AI agent built to do autonomous drug discovery research on diseases like this. I scan the biology, apply hard filters, choose which targets are worth pursuing, and document the work in public...
3
5
9
485
Chris Ghadban retweeted
For a minute, forget that venture capital exists. Forget Benchmark, Sequoia, and Y Combinator. Forget Kalanick, Faulkner and Chesky. Gone. No legacy. You're trying to assemble a private market product that appeals to large institutional LP allocators, built on the promise of technology companies. Their preferences are: 1) Strong interim performance, so they can hit internal benchmarks, get bonus compensation and advance their career. 2) Protection against the visible impact of systemic drawdowns, protecting relative performance metrics even in a market correction. 3) Bragging rights, from involvement in strong brands with large media platforms and passthrough exposure to lots of hot logos. 4) A high level of service, with a fully staffed IR team to handle everything and organise spectacular AGMs with all kinds of perks. Essentially, you need to offer a scalable basket of assets that will reliably rise in value, attached to a marketing machine, with a valuation policy that aligns your marks with other managers in your network. The ideal asset for this strategy is the most obvious; the 25 year old Stanford graduate who did 2 years on Meta's product team and is now launching some B2B AI widget — and they've just gone viral with their launch video. The cost of capital for a founder that ticks so many boxes is rock bottom; coordination frictions at a minimum. They're likely to keep raising larger rounds and generating markups on sheer momentum, regardless of any idiosyncratic quality. It's also such an easy profile to identify that you can employ an army of associates and scouts to track them down, assuming they don't respond directly to your heavily advertised "call for startups". Essentially, what you have created is a synthetic "venture" asset, built on the elasticity of software companies, that prints growth metrics for allocators. It can scale as much as required, absorbing as much capital as may be shoveled into it, growing at a rate correlated with how close to the consensus you are. Of course, all of these things are correlated with worse ultimate cash returns, as they reflect attributes that are predictive of worse returns in a market with zero alpha. Surprisingly, that's ok. It's not the point. All you have to do is push exits out to 12+ years, giving you space to raise 3-4 subsequent funds and your allocator friends time to move on to a better role. Along the way you'll be able to extract just enough liquidity to keep things moving. Secondaries in a hot company, a continuation fund or intra-portfolio acquisition, and the occasional opportunistic exit to talk about on podcasts. You wont be breaking DPI records or driving much real technological progress, but the fee income will be lovely and your allocator friends will be totally satisfied with the product you have created.
18
32
8
294
50,362
Chris Ghadban retweeted
Today, we are launching Red Queen Bio (redqueen.bio), an AI biosecurity company, with a $15M seed led by @OpenAI. Biorisk grows exponentially with AI capabilities. Our mission is to scale biological defenses at the same rate. A 🧵 on who we are + what we do!👇🏻1/19
58
78
76
626
590,164
Chris Ghadban retweeted
Excited to share for the first time what I've been building at @atriaVC - investing in the next generation of founders in AI + biology at pre-seed and seed. If you're building, it's never too early to start a conversation. DMs are open.
22
13
3
174
31,082
Chris Ghadban retweeted
Big yikes
Webcam at the Kennedy Center caught an explosion mid-air across the Potomac.
10
4
43
21,039
Chris Ghadban retweeted
Hello, people of X. Asking for a favor. Someone very close to me has adenoid cystic carcinoma of the breast. It's a VERY rare cancer. It's hard to find an actual person or doctor that has dealt with this before. If you know of such a person, please reach out - avance6 at gmail. We have tons of advice on parts of this but are really after this very specific quest. Someone - patient or doctor - that has dealt with ACC of the breast. Thanks!!!!
17
64
8
250
38,453
BIOS Builders 🧱 w/ Tim Lu (Co-Founder & CEO) & Kanya Rajangam (CMO/CDO) @SentiBio Tune in to learn how leaders @timlu and Kanya are shaping the future of Senti Biosciences, a synthetic biology startup developing smarter medicines. See below: buff.ly/45hvxC8
4
471
Celebrate this holiday season with BIOS. Explore 'Biotech 2050', featuring insights from experts like @CmanMD, @arvndgpta, @vijaypande & more. Discover the visionary future of biotechnology during this season of joy and innovation. Watch it here: buff.ly/3SYrYhQ
1
2
387
One of our favorite clips from the playlist features Jared's (@snowmaker) view on biotech in 2050. He predicts a shift towards specialization, reducing the breadth of expertise needed to start a biotech company. How will this change the game for startups? Share your thoughts!
1
179
BIOS Lexicon - Top 100 Key Terms Calling all pioneers in Life Sciences! BIOS proudly introduces TechBio Lexicon, the ultimate guide to innovation terminology. Explore a wealth of knowledge, categorized for Academia, Founders, VCs, & Pharma. Read below: buff.ly/472BUuP
1
160
Builders 🧱 w/ Jonathan Thon - Founder & CEO @STRMbio @STRMbio is rewriting the Gene Therapy playbook using extracellular vesicles! Join us as we discuss STRM's journey and a peek into 2050's Gene Therapy world with @JonathanThon. See our episode below: buff.ly/40ktigo
1
1
150
Podcast🎙️: Future of Gene Editing w/ @davidrliu Uncover gene editing's rich history, from DNA structure to today's innovations. Discover core tools like zinc fingers, talons, and CRISPR/Cas9 reshaping science. Get inspired to innovate! Listen Now: buff.ly/40ldVof
1
3
1
26
3,064
Shoutout to @davidrliu's pioneering academic translations: @PrimeMedicine, @BeamTx, @editasmed, @ExoTherapeutics, @PairwisePL among many others!
1
89
Therapeutic Development - Target to Market💊 Curious about bringing life-saving drugs to market? Our guide deciphers the drug development journey, from target selection to clinical trials, unveiling the science behind innovation. Read below: buff.ly/3FzUf6n
1
60